Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry

REFERENCES

1. 1.↵
   1. Smolen JS,
   2. Landewe R,
   3. Bijlsma J, et al

   . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Widdifield J,
   2. Paterson JM,
   3. Bernatsky S, et al

   . The epidemiology of rheumatoid arthritis in Ontario, Canada. Arthritis Rheumatol 2014;66:786-93.

   OpenUrlPubMed
3. 3.↵
   1. Burmester GR,
   2. Blanco R,
   3. Charles-Schoeman C, et al; ORAL Step investigators

   . Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Fleischmann R,
   2. Kremer J,
   3. Cush J, et al; ORAL Solo Investigators

   . Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Kremer J,
   2. Li ZG,
   3. Hall S, et al

   . Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253-61.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. van der Heijde D,
   2. Strand V,
   3. Tanaka Y, et al; ORAL Scan Investigators

   . Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study. Arthritis Rheumatol 2019;71:878-91.

   OpenUrl
7. 7.↵
   1. van Vollenhoven RF,
   2. Fleischmann R,
   3. Cohen S, et al

   . Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Caporali R,
   2. Zavaglia D

   . Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2019;37:485-95.

   OpenUrl
9. 9.↵
   1. Finckh A,
   2. Tellenbach C,
   3. Herzog L, et al; SCQM

   . Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open 2020;6: e001174.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Reed GW,
    2. Gerber RA,
    3. Shan Y, et al

    . Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis. Rheumatol Ther 2019;6:573-86.

    OpenUrl
11. 11.↵
    1. Bird P,
    2. Littlejohn G,
    3. Butcher B, et al

    . Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. Clin Rheumatol 2020;39:2545-51.

    OpenUrl
12. 12.↵
    1. Rubin D

    . Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons; 1987.
13. 13.↵
    1. van Buuren S,
    2. Boshuizen HC,
    3. Knook DL

    . Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999;18:681-94.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. D’Agostino RB Jr

    . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Austin PC,
    2. Stuart EA

    . Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34:3661-79.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Granger E,
    2. Sergeant JC,
    3. Lunt M

    . Avoiding pitfalls when combining multiple imputation and propensity scores. Stat Med 2019; 38:5120-32.

    OpenUrlPubMed
17. 17.↵
    1. Harnett J,
    2. Gerber R,
    3. Gruben D,
    4. Koenig AS,
    5. Chen C

    . Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Manag Care Spec Pharm 2016;22:1457-71.

    OpenUrl
18. 18.↵
    1. Fleischmann R,
    2. van Adelsberg J,
    3. Lin Y, et al

    . Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol 2017;69:277-90.

    OpenUrl
19. 19.
    1. Genovese MC,
    2. Fleischmann R,
    3. Kivitz AJ, et al

    . Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol 2015;67:1424-37.

    OpenUrlPubMed
20. 20.
    1. Keystone E,
    2. van der Heijde D,
    3. Mason D Jr, et al

    . Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.

    OpenUrlCrossRefPubMed
21. 21.
    1. Keystone EC,
    2. Genovese MC,
    3. Klareskog L, et al

    . Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.

    OpenUrlAbstract/FREE Full Text
22. 22.
    1. Keystone EC,
    2. Kavanaugh AF,
    3. Sharp JT, et al

    . Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.

    OpenUrlCrossRefPubMed
23. 23.
    1. Maini R,
    2. St Clair EW,
    3. Breedveld F, et al

    . Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.

    OpenUrlCrossRefPubMed
24. 24.
    1. Moreland LW,
    2. Schiff MH,
    3. Baumgartner SW, et al

    . Etanercept therapy in rheumatoid arthritis. a randomized, controlled trial. Ann Intern Med 1999;130:478-86.

    OpenUrlCrossRefPubMed
25. 25.
    1. Smolen J,
    2. Landewe RB,
    3. Mease P, et al

    . Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.

    OpenUrlAbstract/FREE Full Text
26. 26.
    1. Smolen JS,
    2. Kay J,
    3. Doyle MK, et al; GO-AFTER study investigators

    . Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.

    OpenUrlCrossRefPubMed
27. 27.
    1. Smolen JS,
    2. van Vollenhoven R,
    3. Kavanaugh A, et al

    . Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Res Ther 2015;17:245.

    OpenUrl
28. 28.
    1. van de Putte LB,
    2. Atkins C,
    3. Malaise M, et al

    . Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.

    OpenUrlAbstract/FREE Full Text
29. 29.
    1. Weinblatt ME,
    2. Bingham CO , 3rd,
    3. Mendelsohn AM, et al

    . Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013;72:381-9.

    OpenUrlAbstract/FREE Full Text
30. 30.
    1. Weinblatt ME,
    2. Keystone EC,
    3. Furst DE, et al

    . Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Weinblatt ME,
    2. Kremer JM,
    3. Bankhurst AD, et al

    . A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.

    OpenUrlCrossRefPubMed